INMB - INmune Bio Inc
IEX Last Trade
6.6
-0.260 -3.939%
Share volume: 110,251
Last Updated: Fri 30 Aug 2024 09:59:56 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.86
-0.26
-3.79%
View ratios
| Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
| Report Date | 2022-11-02 | 2023-03-02 | 2023-05-03 | 2023-08-07 | 2023-11-01 | 2024-03-28 | 2024-05-09 | 2024-08-01 | |
| Assets | |||||||||
| Total Assets | 83.800 M | 81.795 M | 73.979 M | 69.720 M | 62.698 M | 57.001 M | 46.833 M | 52.453 M | |
| Current Assets | 66.658 M | 64.675 M | 56.881 M | 52.608 M | 45.611 M | 39.942 M | 29.824 M | 35.495 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 4.722 M | 4.061 M | 3.668 M | 2.737 M | 1.535 M | 1.652 M | 1.132 M | 1.013 M | |
| Short Term Investments | 4.722 M | 4.061 M | 3.668 M | 2.737 M | 1.535 M | 1.652 M | 1.132 M | 1.013 M | |
| Total Receivables | 4.531 M | 8.461 M | 2.210 M | 2.046 M | 2.263 M | 2.442 M | 2.690 M | 3.413 M | |
| Current Cash | 57.405 M | 52.153 M | 51.003 M | 47.825 M | 41.813 M | 35.848 M | 26.002 M | 31.069 M | |
| Total Non-current Assets | 17.142 M | 17.120 M | 17.098 M | 17.112 M | 17.087 M | 17.059 M | 17.009 M | 16.958 M | |
| Property Plant Equipment | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Assets | 628.000 K | 606.000 K | 584.000 K | 598.000 K | 573.000 K | 545.000 K | 495.000 K | 444.000 K | |
| Intangible Assets | 16.514 M | 16.514 M | 16.514 M | 16.514 M | 16.514 M | 16.514 M | 16.514 M | 16.514 M | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 83.800 M | 81.795 M | 73.979 M | 69.720 M | 62.698 M | 57.001 M | 46.833 M | 52.453 M | |
| Total liabilities | 20.094 M | 21.691 M | 18.683 M | 19.066 M | 17.966 M | 19.661 M | 18.609 M | 16.172 M | |
| Total current liabilities | 6.895 M | 10.918 M | 10.283 M | 13.055 M | 14.356 M | 18.465 M | 17.450 M | 15.051 M | |
| Accounts Payable | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 463.000 K | 550.000 K | 638.000 K | 726.000 K | 804.000 K | 799.000 K | 799.000 K | 799.000 K | |
| Current long term debt | 2.644 M | 5.087 M | 7.606 M | 10.101 M | 10.106 M | 10.040 M | 7.580 M | 5.109 M | |
| Long term debt | 12.736 M | 10.223 M | 7.762 M | 5.285 M | 2.806 M | 397.000 K | 360.000 K | 322.000 K | |
| Other liabilities | 463.000 K | 550.000 K | 638.000 K | 726.000 K | 804.000 K | 799.000 K | 799.000 K | 799.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 63.706 M | 60.104 M | 55.296 M | 50.654 M | 44.732 M | 37.340 M | 28.224 M | 36.281 M | |
| Common stock | 17.946 M | 17.947 M | 17.946 M | 17.946 M | 18.008 M | 18.023 M | 18.026 M | 19.307 M | |
| Retained earnings | -85.181 M | -91.014 M | -97.550 M | -104.051 M | -112.614 M | -121.022 M | -132.047 M | -141.793 M |